Portal de Periódicos da CAPES

Australian recommendations on tapering of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs in inflammatory arthritis

2022; Wiley; Volume: 52; Issue: 10 Linguagem: Inglês

10.1111/imj.15816

1445-5994

Samuel Whittle, Vanessa Glennon, Renea V Johnston, Jodie Avery, J. Simon Bell, Sue Brennan, Christopher Fong, Pravin Hissaria, Ben Horgan, Sean O’Neill, Huai Leng Pisaniello, Lyndal Trevena, Glen A. Whittaker, Anita E. Wluka, Rachelle Buchbinder,

Psoriasis: Treatment and Pathogenesis

Biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) have been an important advance in the management of inflammatory arthritis, but are expensive medications, carry a risk of infection and other adverse effects, and are often perceived as a burden by patients. We used GRADE methodology to develop recommendations for dose reduction and discontinuation of b/tsDMARD in people with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) who have achieved a low disease activity state or remission. The recommendations form part of the Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis, an NHMRC-endorsed 'living' guideline, in which recommendations are updated in near real-time as new evidence emerges. Conditional recommendations were made in favour of dose reduction in RA and AxSpA but not in PsA. Abrupt discontinuation of b/tsDMARD is not recommended in any of the three diseases.